RE:RE:RE:RE:RE:RE:RE:RE:Earnings call suggestionAdd to that incompetency and lack of engagement, low rating and biased opinion then you end up with folks like Loe and Nash.
“We have analyzed the value of sell-side ratings, and whether following them is associated with investment returns,” Cowen’s analysts wrote in their report Monday. “Unfortunately (for our job security and sense of self-worth), we find that over the last four years there was an overall inverse correlation between sell-side ratings and rating changes and the performance of biotechnology stocks.” Spartrap wrote: Sell side analysts' ratings have been a proven contrarian signal in biotech for some time now..
https://www.cnbc.com/2018/07/02/when-analysts-say-sell-a-biotech-stock-its-time-to-buy.html
scarlet1967 wrote: I know which makes it more difficult to understand, not engaged at all, didn't even bothered to ask questions yet he produced a report based on the PR. Time to bypass the analysts for now as it seems they only adjust their reports after the fact.
palinc2000 wrote: He wasn't even on the Call,,,,
scarlet1967 wrote: This is what happens when one is trying hard to work with incompetent analysts only.
Douglas W. Loe, at Leeds Jones downgraded the company to hold from speculative buy.